Chairman of the Board

Chairman of the Board

GE LI, PHD.

Dr. Ge Li is the Founder, Chairman and Chief Executive Officer of WuXi AppTec, a leading R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries with 12,000 employees and 25 R&D sites and offices worldwide.

A pioneer in biopharma R&D service industry in China, Dr. Li founded WuXi in December 2000 with four employees, China’s first modern chemistry hood, and a single 7,000-square-foot chemistry laboratory. During the past 15 years as its Chairman and CEO, Dr. Li has led WuXi’s rapid growth into a global R&D enabling powerhouse with a pioneering open-access platform as the cornerstone. Today, WuXi’s platform is enabling thousands of biopharma and medical device R&D programs from over 2000 collaborators worldwide. 

Dr. Li's visionary leadership and achievements have won him numerous prestigious awards and honors, including the “2016 CBA Brilliant Achievement Award”, “2015 SCRIP Executive of the Year Award”, “The 25 Most Influential People in Biopharma in 2015”, “Forbes 25 Notable Chinese-Americans”, “The 60 Most Influential People during 60 Years Pharmaceutical Development in China”, and “Ernst & Young Entrepreneur of the Year China Award”. 

 Dr. Li earned his bachelor’s degree in Chemistry from Peking University and his doctoral degree in Organic Chemistry from Columbia University. Prior to WuXi, Dr. Li was a founding scientist at Pharmacopeia Inc., a leading combinatorial chemistry platform company. 

 

 

 Director

Director

EDWARD HU

Mr. Edward Hu, is currently Chief Financial Officer & Chief Investment Officer at WuXi AppTec. In this capacity, Mr. Hu manages WuXi’s finance, strategic investments, merger and acquisition, and new business building. In addition, He also manages WuXi’s joint ventures with MedImmune and PRA. Mr. Hu is Head of WuXi Corporate Venture Fund, spearheading the fund’s investment strategy and portfolio management. Previously, he served as WuXi’s Chief Operating Officer and Chief Financial Officer. Prior to joining WuXi, Mr. Hu was SVP and Chief Operating Officer at Tanox, responsible for operations, finance, IT, project management and strategic planning, and managed the acquisition of Tanox by Genentech in 2007. He also held positions at Merck & Co., Inc. as a Senior Financial Analyst and later in Business and Financial Planning Manager at Biogen, Inc. (n/k/a Biogen Idec, Inc.), where he managed the business planning of Biogen's R&D and clinical development programs, and provided project planning and analysis support to key drug development project teams. Mr. Hu completed his Ph.D. work, all but dissertation, in Biophysics and Biochemistry at Carnegie Mellon University, where he also received his MBA degree. 

 

 

 Director

Director

HANS BISHOP

Hans E. Bishop is one of our co-founders and has served as our Chief Executive Officer and a member of our Board of Directors since September 2013. Mr. Bishop has also served as a member of the Board of Directors of Avanir Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, since May 2012. Mr. Bishop previously served as Chairman of the Board of Genesis Biopharma, Inc., a biotechnology company, from January 2012 until November 2012. From February 2012 until October 2012, Mr. Bishop was the Chief Operating Officer of PhotoThera, Inc., a late-stage medical device company owned by Warburg Pincus, and he continued working with Warburg Pincus as an Executive in Residence until October 2013. Mr. Bishop previously served as Executive Vice President and Chief Operating Officer at Dendreon Corporation, a cancer cell therapy company, from January 2010 to September 2011.

Mr. Bishop has also served as the President of the Specialty Medicine Business at Bayer Healthcare Pharmaceuticals, Inc. from December 2006 to January 2010, where he was responsible for a diverse portfolio of neurology, oncology, and hematology products. Mr. Bishop was employed by Chiron Corporation as Senior Vice President of Global Commercial Operations until its sale to Novartis Corporation. Mr. Bishop received a B.Sc. in Chemistry from Brunel University in London.

 
 
 Director

Director

Steve Harr

Steven D. Harr is our Chief Financial Officer and Head of Corporate Development and joined Juno in April 2014. Dr. Harr was Managing Director and Head of Biotechnology Investment Banking at Morgan Stanley from May 2010 until he joined Juno. Prior to his investment banking role at Morgan Stanley, Dr. Harr was Morgan Stanley’s lead biotech research analyst and Co-Head of Global Healthcare Research. Dr. Harr received a B.A. in Economics from College of the Holy Cross and an M.D. from The Johns Hopkins University School of Medicine. Dr. Harr was a resident in internal medicine at the University of California, San Francisco.

 

 

 

 

 

 

 Chief Executive Officer

Chief Executive Officer

James Li, MD.

Dr. James Li was the founding General Manager for Amgen in China, where he led the company's efforts in expanding its business into the Chinese market to help Chinese patients gain access to Amgen's vital medicines.


Prior to joining Amgen, James was a Partner at Kleiner Perkins Caufield & Byers life science practice, first in the US Pandemic Fund and later, in its China Fund. He successfully invested in early stage university spin out, growth stage companies and led a portfolio company went to public in 2010.


From 1991 to 2006, James spent over 15 years with Merck Co. & Inc. where he held leadership positions with increasing responsibilities in clinical research, regulatory affairs, new product development and franchise management, both in the US and Asia Pacific/China. During his tenure, he was instrumental in obtaining regulatory approvals of Merck vaccines across Asia Pacific Region when the Vaccine Division started operations in the region, successfully built the foundations of Merck's medical operations in China and drove the success of Merck's largest franchise in Asia.

James received his Medical Degree from Shanghai Medical University followed by a Master of Science degree in Microbiology from the University of Montana.